GoodRx Holdings, Inc. (GDRX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 1.16B USD | Liabilities, Current |
| Cash and equivalents | 296.11M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 182.14M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.16B | $296.11M | (m) | $182.14M | (m) | (m) |
| 2026-03-31 | (m) | $859.20M | $235.71M | (m) | $232.72M | (m) | (m) |
| 2025-12-31 | (m) | $246.00M | $261.82M | (m) | $235.75M | (m) | (m) |
| 2025-09-30 | (m) | $181.86M | $273.53M | (m) | $203.74M | (m) | (m) |
| 2025-06-30 | (m) | $130.91M | $281.32M | (m) | $189.03M | (m) | (m) |
| 2025-03-31 | (m) | $103.38M | $300.98M | (m) | $160.12M | (m) | (m) |
| 2024-12-31 | (m) | $123.90M | $448.35M | (m) | $145.93M | (m) | (m) |
| 2024-09-30 | (m) | $114.36M | $423.78M | (m) | $130.80M | (m) | (m) |
| 2024-06-30 | (m) | $102.47M | $524.90M | (m) | $161.77M | (m) | (m) |
| 2024-03-31 | (m) | $116.52M | $533.29M | (m) | $144.77M | (m) | (m) |
| 2023-12-31 | (m) | $122.56M | $672.30M | (m) | $143.61M | (m) | (m) |
| 2023-09-30 | (m) | $117.82M | $794.90M | (m) | $121.15M | (m) | (m) |
| 2023-06-30 | (m) | $82.55M | $761.99M | (m) | $123.38M | (m) | (m) |
| 2023-03-31 | (m) | $68.98M | $761.08M | (m) | $116.44M | (m) | (m) |
| 2022-12-31 | (m) | $76.32M | $757.16M | (m) | $117.14M | (m) | (m) |
| 2022-09-30 | (m) | $84.97M | $728.79M | (m) | $120.89M | (m) | (m) |
| 2022-06-30 | (m) | $79.62M | $730.54M | (m) | $122.88M | (m) | (m) |
| 2022-03-31 | (m) | $59.36M | $845.43M | (m) | $123.28M | (m) | (m) |
| 2021-12-31 | (m) | $81.11M | $941.11M | (m) | $118.08M | (m) | (m) |
| 2021-09-30 | (m) | $72.68M | $912.02M | (m) | $98.51M | (m) | (m) |
| 2021-06-30 | (m) | $65.49M | $894.70M | (m) | $87.00M | (m) | (m) |
| 2021-03-31 | (m) | $63.05M | $990.46M | (m) | $74.40M | (m) | (m) |
| 2020-12-31 | (m) | $59.55M | $968.69M | (m) | $68.73M | (m) | (m) |
| 2020-09-30 | (m) | $60.16M | $1.08B | (m) | $63.52M | (m) | (m) |
| 2020-06-30 | (m) | (m) | $126.63M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $95.84M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $33.37M | $26.05M | (m) | $48.13M | (m) | (m) |
| 2019-09-30 | (m) | (m) | $59.69M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | $34.60M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.